Previous Article | Next Article ![]()
Mol Cell Biol, July 1998, p. 4165-4176, Vol. 18, No. 7
Department of Viral Oncology, Institute for
Virus Research, Kyoto University, Shogoin, Sakyo-ku, Kyoto 606, Japan
Received 26 January 1998/Returned for modification 19 February
1998/Accepted 28 April 1998
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The Capacity of Polyomavirus Enhancer Binding
Protein 2
B (AML1/Cbfa2) To Stimulate Polyomavirus DNA
Replication Is Related to Its Affinity for the Nuclear
Matrix
SUMMARY
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
ACKNOWLEDGMENTS
REFERENCES
SUMMARY
|
|
|---|
The nuclear matrix is thought to play an important role in the DNA
replication of eukaryotic cells, although direct evidence for such a
role is still lacking. A nuclear matrix-associated transcription
factor, polyomavirus (Py) enhancer binding protein 2
B1 (PEBP2
B1)
(AML1/Cbfa2), was found to stimulate Py replication through its cognate
binding site. The minimal replication activation domain (RAD) was
identified between amino acid (aa) 302 and aa 371 by using a fusion
protein containing the GAL4 DNA binding domain (GAL4-RAD). In addition,
the region showed affinity for the nuclear matrix and, on the basis of
competition studies, binding activity for one or more proteins involved
in the initiation of Py DNA replication. A leukemogenic chimeric
protein, AML1/ETO(MTG8), which does not contain this region of
PEBP2
B1/AML1, was also localized in the nuclear matrix fraction and
competed for nuclear matrix association with PEBP2
B1 and GAL4-RAD.
Moreover, AML1/ETO inhibited Py DNA replication stimulated by
PEBP2
B1 and GAL4-RAD. The inhibition was specific for replication
mediated by PEBP2
B1 and GAL4-RAD, and proportional to the degree of
loss of these activators from the nuclear matrix, suggesting a
requirement for nuclear matrix targeting in the stimulation of Py DNA
replication by RAD. These results are the first to suggest a molecular
link between the initiation of DNA replication and the nuclear matrix compartment.
INTRODUCTION
|
|
|---|
Accumulating evidence suggests an
involvement of transcription factors in the regulation of DNA
replication in eukaryotic cells. The polyomavirus (Py) DNA replication
system is ideal for elucidating the roles of transcription factors in
DNA replication, as Py DNA replicates in the nuclei of rodent cells and
relies entirely on host factors, except for a single viral protein,
large T antigen (TAg). The Py origin of replication contains a
transcription enhancer in addition to a core sequence of the origin
(ori-core). The ori-core contains binding sites
for TAg and determines where replication begins, while the enhancer
stimulates Py DNA replication 200- to 1,000-fold and determines the
tissue specificity of DNA replication (12). The enhancer
sequence can be replaced with multiple copies of a binding site for a
single transcription factor (18, 42, 51). In this case, the
initiation of Py DNA replication becomes dependent on a single
transcription factor, thus allowing an analysis of the properties of
each transcription factor with respect to its capacity to stimulate Py
DNA replication. By using this system, we and others showed that
transcription factors such as AP1 (18, 42, 51), VP16, GAL4
(5, 6, 18), c-Rel/NF-
B (24), bovine papilloma
virus E2 (44), and p53 (30) are able to stimulate
Py DNA replication when the Py enhancer is replaced by the binding
sites for these factors.
So far, all transcription factors with replication-enhancing activity appear to require an activation domain, in addition to the DNA binding domain. The activation domain for replication overlaps that for transcription in many cases. For example, a yeast transcription factor, GAL4, requires the transcriptional activation domain to stimulate Py DNA replication, and the domain can be functionally replaced with transcriptional activation domains from other transcription factors such as VP16 and c-Jun (5, 6, 18). However, both domains are not necessarily identical. We showed that one of the two replication activation domains of p53, which mapped to the C-terminal region, did not stimulate transcription, while the other domain overlapped the transcription activation domain in the N-terminal region (30). Similarly, the Rel homology region in the N-terminal region of c-Rel stimulated Py DNA replication but not transcription, in contrast to the C-terminal transactivation domain, which enhanced both transcription and DNA replication (24). By analogy with transcription activation domains, one may imagine that the replication activation domain stimulates Py DNA replication through interaction with factors participating in the initiation of Py DNA replication. Indeed, the activation domains of VP16, GAL4, E2, and p53 (both domains) were shown to interact with a single-stranded-DNA binding protein, replication protein A (RP-A), which is essential for the initiation of Py DNA replication (13, 21, 35). More recently, we showed that c-Jun interacts with TAg to stimulate the formation of the core origin-TAg initiation complex (26).
Polyomavirus enhancer binding protein 2 (PEBP2) binds to DNA within the
core elements of the Py enhancer which are important for replication
(29, 41). PEBP2 is a heterodimer of two subunits,
and
(45, 46). There are three genes which encode the
subunits of PEBP2: PEBP2
A (also called CBFA1
and AML3) (45), PEBP2
B (also called
CBFA2 and AML1) (3), and
PEBP2
C (also called CBFA3 and AML2)
(4). The
subunit is a homolog of the products of the
Drosophila developmental regulator genes runt and
lozenge. Two Drosophila genes which are
homologous to the
subunit genes, brother and big
brother, were identified (17). The
subunit has DNA
binding activity, and the
subunit stimulates DNA binding activity
of the
subunit. There are two functional regions within the
subunit of PEBP2. The evolutionarily conserved 128-amino-acid region
termed the Runt domain is responsible for binding to DNA and dimerizing
with the
subunit (28, 38, 46). The region downstream of
the Runt domain is required for transcription activation (3,
31). Results from homozygous disruption of PEBP2
B
in the mouse indicated that the factor is essential for definitive
hematopoiesis (47, 50). Indeed, many genes important in
regulating growth and differentiation of hematopoietic cells have been
found to be regulated by PEBP2
B. The most characteristic feature of
PEBP2 is that it is involved in context-dependent transcription activation: it intimately interacts with several other transcription factors and cooperates with them for either DNA binding or
transcription activation (31).
PEBP2
B corresponds to the human gene AML1
(15, 39), which is rearranged in the 8-to-21 chromosome
translocation, t(8;21), the most frequent chromosomal translocation
found in acute myelogenous leukemia. The t(8;21) translocation produces
the AML1/ETO(MTG8) chimeric protein, in which the region between the N
terminus and Runt domain of AML1 is fused to ETO (15, 39).
In this paper, murine AML1 is referred to as PEBP2
B and the
full-length product of 451 amino acids is referred to as PEBP2
B1.
Recent experiments suggest that many nuclear events such as
transcription and DNA replication are linked to the organization of
nuclear structure, and especially to the filamentous ribonucleoprotein complex. This structure is alternatively referred to as the nuclear matrix, scaffold, or skeleton, depending on the isolation procedure. For simplification, we use the term "nuclear matrix" herein. The nuclear matrix is thought to contribute to replication and
transcription by localizing or concentrating the factors implicated in
these processes. For example, in mammalian cells, DNA replication
appears to take place in specialized nuclear substructures which can be visualized as replication foci by immunolabeling of the incorporated analog, bromodeoxyuridine (43). The foci are attached to the nuclear matrix and contain proteins involved in DNA replication, such
as DNA polymerase
, proliferating cell nuclear antigen, and RP-A.
Such foci have been referred to as replication "factories" (23). Although no precise role has been ascribed to such
structures, one possibility is that efficient initiation of DNA
replication requires the attachment of origins to the nuclear matrix.
Indeed, most of the autonomously replicating sequences in
Saccharomyces cerevisiae and Schizosaccharomyces
pombe, which in most cases function as origins of replication in
their chromosomal DNA contexts, are bound to the nuclear matrix
(1, 2).
Recently, Merriman et al. reported that the PEBP2-related transcription factor NMP-2, which binds to the PEBP2 binding sequence in the osteocalcin promoter, is exclusively localized in the nuclear matrix of osseous cells (37). More recently, Zeng et al. showed that AML1 is localized in the nuclear matrix and identified a nuclear matrix targeting sequence within AML1 near the transactivation domain (54). However, the importance of the nuclear matrix localization in the function of PEBP2 is not clear.
In this study, we showed that PEBP2 can stimulate Py DNA replication by itself. This enabled us to examine the role of the nuclear matrix compartment in the stimulation of Py DNA replication. We mapped a replication activation domain (RAD) of 70 amino acids within the region C terminal to the Runt domain. Interestingly, the RAD appears to provide two properties: nuclear matrix targeting and affinity for a DNA replication protein. By using the chimeric protein AML1/ETO, which inhibited both activities, we demonstrate that nuclear matrix targeting of RAD is important for the stimulation of DNA replication by RAD.
MATERIALS AND METHODS
|
|
|---|
Cell culture and transfection. P19 cells, a murine embryonal carcinoma cell line, were maintained in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham F-12 medium supplemented with 10% (vol/vol) fetal bovine serum at 37°C. P19 cells were plated at 5 × 105 cells per 100-mm-diameter dish 10 h before transfection. The indicated amount of plasmid DNA was transfected by a modified Chen-Okayama calcium phosphate procedure (7). For each dish, the total amount of DNA used for transfection was adjusted to 15 to 20 µg by the addition of the backbone vector to the effector plasmids. Sixteen hours after transfection, the precipitates were washed and the cells were incubated for a further 24 h. Then the cells were harvested for further analysis. All transfection experiments were repeated independently at least three times.
Plasmids.
The reporter plasmid pPy(AE)4OICAT was
a derivative of pPyOICAT. The double-stranded oligonucleotides
representing four repeats of the PEBP2 binding site derived from the A
core of the polyomavirus enhancer sequence (41) were
inserted between the HindIII and BglII sites
of pPyOICAT. The reporter plasmid pPyG5OICAT contains five copies of
the yeast GAL4 DNA-binding motif (24). Plasmids for
expression of Py TAg and various deletion proteins of PEBP2
B1 were
derived from pEF-BOS (40) and described previously (30, 31). A series of deletions of PEBP2
B1 (amino acid [aa] 262 to aa 371) were generated by PCR amplification by using various sets of
primers containing BamHI sites at both ends. To make fusion proteins with the GAL4 DNA binding domain (1 to 147), the
BamHI-BglII VP16 fragment of pSGGAL4-VP16
(16) was replaced by the PCR products digested with
BamHI. The introduction of point mutations was performed with an in vitro PCR-based site-directed mutagenesis kit (Stratagene) by using pSG-GAL4/PEBP2
B1 (aa 302 to aa 371) as a template and the
synthetic oligonucleotides as mutagenic primers. The DNA sequence was
confirmed by dideoxy sequencing with Sequenase version 2.0 (Amersham).
Replication assay. Reporter plasmids (0.2 µg), effector plasmids (0.5 µg for plasmids based on pEF-BOS and 2 µg for plasmids which express GAL4 fusion proteins), the Py TAg expression plasmid pEF-BOS LT (4 µg), and the DpnI-resistant pHSG398 control plasmid (0.8 µg), which was prepared from dam mutant Escherichia coli GM33, were cotransfected into P19 cells as described above. Low-molecular-weight DNAs were isolated by the Hirt procedure (22). Purified DNAs were digested with HindIII and DpnI to convert replicated molecules and the control plasmid into their linear forms and to eliminate unreplicated DNA. Digested DNA was fractionated by 0.8% agarose gel electrophoresis, blotted onto Hybond N+ (Amersham), and then detected by hybridization with the BamHI-EcoRI fragment of pPyOICAT containing a part of the chloramphenicol acetyltransferase (CAT) gene as a hybridization probe. The radioactivity in the bands representing replicated and control DNAs was quantified with a BAS2000 analyzer (Fuji) and normalized with respect to the bands of the control DpnI-resistant plasmid.
Preparation of cellular fractions and nuclear skeleton. The isolation of the nuclear matrix/scaffold fraction and other cellular fractions was performed according to the method described by Merriman et al. (37). Briefly, transfected cells were harvested and sequentially extracted with cytoskeleton (CSK) buffer (100 mM NaCl, 300 mM sucrose, 10 mM PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid)] [pH 6.8], 3 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100 and 1.2 mM phenylmethylsulfonyl fluoride [PMSF]) and reticulocyte standard buffer (RSB)-Majik buffer (100 mM NaCl, 10 mM Tris [pH 7.4], 3 mM MgCl2, 1.0% Tween 40, 0.5% deoxycholate [Na salt], and 1.2 mM PMSF). The extract with CSK buffer was used as the soluble fraction. Then the pellet was incubated with digestion buffer (50 mM NaCl, 300 mM sucrose, 10 mM PIPES [pH 6.8], 3 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, and 1.2 mM PMSF) containing DNase I (100 µg/ml) and RNase A (50 µg/ml) for 20 min at room temperature. After digestion, ammonium sulfate was added to a final concentration of 250 mM, and the nuclear matrix fraction was recovered by short centrifugation (880 × g, 10 min). The remaining supernatant was used as the chromatin fraction. Different fractions of the cells and the nuclear matrix were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Nuclear skeleton was isolated as described by Hozak et al. (23). Briefly, transfected P19 cells were harvested and encapsulated in 0.5% low-melting-point agarose (FMC). Encapsulated cells were treated with streptolysin O (1,000 U/ml per 106 cells) (Sigma) in phosphate-buffered saline (PBS) and permeabilized with physiological buffer (pH 7.4). Physiological buffer contains 130 mM KCl, 10 mM Na2HPO4, 1 mM MgCl2, 1 mM Na2ATP, 1 mM dithiothreitol, and 0.1 mM PMSF, and the pH was adjusted to 7.4 by adding 100 mM KH2PO4. Alternatively, encapsulated cells were permeabilized by incubation with 0.5% Triton X-100 in physiological buffer. Encapsulated and permeabilized cells were digested with DNase I (100 µg/ml) and RNase A (50 µg/ml) in a physiological buffer and then subjected to electrophoresis in 0.8% agarose gel at 4 V/cm for 4 h. After electrophoresis, agarose beads were harvested, treated with
-agarase
(1 U/200 µl) (FMC) at 45°C for 60 min, and then centrifuged
(880 × g, 10 min). The pellets were considered nuclear
skeleton and were subjected to SDS-PAGE for Western blot analysis.
Western blot analysis.
A total of 10% of the different
fractions of the harvested cells isolated as described above were
separated by SDS-12% PAGE. The proteins in the gel were transferred
electrophoretically (at 40 V for 12 h) onto a reinforced cellulose
nitrate membrane (Schleicher & Schuell). The blocking reaction was
performed by shaking the membrane for 1 h in PBS (80 mM
Na2HPO4, 20 mM NaH2PO4,
and 100 mM NaCl) containing 0.1% Tween 20 and 10% nonfat dry milk.
The membrane was incubated for 1 h with the 2,000-fold diluted
polyclonal antibody directed against the full-length PEBP2
B1 or the
polyclonal anti-yeast GAL4 antibody (UBI) in PBS containing 0.1% Tween
20 and 5% nonfat dry milk. After washing in PBS containing 0.1% Tween 20, the membrane was incubated for 1 h with 5,000-fold diluted goat anti-rabbit immunoglobulin G conjugated with peroxidase (Zymed Laboratories, Inc.). Proteins were visualized by using the ECL Western
blotting analysis system (Amersham Life Science) and quantified by
densitometric scanning of the films.
Electrophoretic mobility shift assay (EMSA).
AML1/ETO, CH15,
and 1-185 were in vitro translated by using the TNT reticulocyte-lysate
system (Promega, Madison, Wis.). Equal amounts of the translated
products were used in the reaction with the 32P-labeled
probe M4A (52). E. coli-produced
2
(46) was added when indicated, and the DNA binding reaction
and electrophoresis were carried out as described previously
(3).
RESULTS
|
|
|---|
PEBP2
B1 stimulates Py DNA replication in a binding
site-dependent manner.
We cotransfected the reporter plasmid and
an effector plasmid expressing PEBP2
B1 into P19 cells, which
expresses the
subunit but not the
subunits of PEBP2 (3,
46). Figure 1 shows that PEBP2
B1
stimulated replication of Py(AE)4OICAT in a dose-dependent manner (lanes 4 to 9) but not Py(AEM)6OICAT, which contains
mutations in the PEBP2 DNA binding sites (lanes 10 to 15). The
replication activity of Py(AE)4OICAT shown in Fig. 1
represents authentic Py DNA replication, because this activity was
completely dependent on both Py TAg (lane 2) and the core origin of
replication (lane 3).
|
The C-terminal region of the PEBP2
B1 is responsible for the
activation of Py DNA replication.
In order to identify regions of
PEBP2
B1 required for the activation of Py DNA replication, a series
of deletion mutants of PEBP2
B1 was constructed (Fig.
2A). We tested the DNA binding properties
of all the deletion mutants by EMSA by using whole-cell extracts
prepared from P19 cells transfected with each of these expression
plasmids. All the mutants showed DNA binding activity except 70-451 (data not shown). 70-451 lacks the 20-aa region of the Runt domain that
is essential for DNA binding activity (28). In addition, we
confirmed that PEBP2
B1 and its deletion derivatives were capable of
forming heterodimers with the
subunit because anti-
subunit
antibody caused a supershift of each of the shifted bands in EMSA (data
not shown).
|
B1 (Fig. 2A and B, lane 6). When the C-terminal
deletion extended as far as aa 331, the activity was reduced to 25% of
the full-length protein (Fig. 2B, lane 7). Further deletion up to aa
291 completely abolished the activity. These results indicated that the
region between aa 291 and 371 was primarily responsible for the
activity. Both 1-185 and 50-185 could bind to the
subunit, and the
resultant complexes bound to DNA but could not stimulate Py replication
(Fig. 2B, lanes 10 and 14), indicating that the
subunit does not
independently contribute to the stimulation of DNA replication (data
not shown).
The replication activation domain can function when it is fused to
the GAL4 DNA binding domain.
In order to see whether the
replication activation activity can function when the activation domain
is fused to a heterologous DNA binding domain, as was observed with
c-Rel (24), we dissected the C-terminal region of PEBP2
B1
into several subregions and fused them to the GAL4 DNA binding domain
(Fig. 3A). We confirmed that each fusion
protein was expressed at a comparable level in P19 cells by Western
blotting (data not shown).
|
B1 fused to the GAL4
DNA binding domain (B6 [aa 178 to 411]) activated Py DNA replication
(lane 5). We further delineated the activation domain by using GAL4
fusion constructs. Consistent with the results shown above, the
deletion from the C terminus to aa 371 did not affect the activity (B7
[Fig. 3B, lane 6]), but the deletion extending up to aa 291 (B3
[Fig. 3B, lane 3]) eliminated the activity. The smallest fusion
protein, B5 (aa 262 to 371), strongly activated DNA replication
(compare lane 4 with lane 7): B5 showed 10-fold-higher activity than
the control, which is comparable to the level of the full-length
PEBP2
B1 (Fig. 1). From the results of these experiments, we
concluded that the region spanning aa 262 to 371 harbors the main part
of the domain responsible for stimulation of Py DNA replication.
To narrow down the replication activation region further, we
constructed a series of deletion mutants of B5. Figure
4A illustrates the structure of the 14 deletion constructs used. We confirmed that all the fusion proteins
showed DNA binding activities by EMSA (data not shown). We tested the
stimulatory activity of each fusion protein for Py DNA replication as
well as for transcription, and the results are shown in Fig. 4A and B. The N-terminal deletion up to aa 302 (Fig. 4B, lane 6) did not affect
replication activity significantly. The truncated fragment, aa 302 to
371, still retained about 80% of the activity compared to the entire
fragment. A further N-terminal deletion up to aa 312 (Fig. 4B, lane 7)
sharply reduced the activity to 25% of that of B5. From the C
terminus, a deletion up to aa 362 (Fig. 4B, lane 11) had little effect
on the activity. Further deletions resulted in a gradual reduction in
activity (Fig. 4B, lanes 9 and 10). However, the 60-aa fragment between aa 302 and 362 retained only about half of the activity of the original
fragment (Fig. 4B, lane 15). The most likely interpretation is that
functional redundancy exists between aa 262 to 302 and aa 362 to 371. One of these regions was required for maximum stimulation of DNA
replication (compare the activities of the regions from aa 262 to 362, 302 to 371, and 302 to 362). From these results, we chose the 70 aa
from 302 to 371 as a minimal RAD.
|
RAD is attached to the nuclear matrix, and AML1/ETO interferes with
its attachment.
Zeng et al. reported that AML1 is exclusively
localized in the nuclear matrix and that the nuclear matrix targeting
signal maps to the region between aa 351 and 381, which corresponds to aa 324 and 353, respectively, in our numbering system (3). This targeting signal is comprised within RAD. We first examined the
subnuclear localization of PEBP2
B1 and found that it was mainly
present in the nuclear matrix fraction, with only a small portion
appearing in the chromatin fraction; more than 80% of the protein was
in the nuclear matrix fraction (Fig. 5B).
Consistent with the observation that RAD contains the nuclear matrix
targeting signal, more than 70% of the GAL4-RAD fusion protein was
found to be present in the nuclear matrix fraction, whereas less than 25% of the protein containing only the GAL4 DNA binding domain was in
the same fraction (Fig. 5B), as observed by Zeng et al. (54).
|
B1 or GAL4-RAD expressing plasmid and analyzed their relative
amounts in the nuclear matrix fraction. The results showed that
increasing amounts of AML1/ETO progressively decreased the amount of
PEBP2
B1 in the nuclear matrix fraction (Fig. 5C). The amount of
PEBP2
B1 did not vary appreciably throughout the experiment (data not
shown). Coexpression of AML1/ETO (Fig. 5D) but not CH15 (Fig. 5D)
interfered with the nuclear matrix localization of GAL4-RAD. In
contrast, the nuclear matrix localization of GAL4-VP16 was not affected by coexpression of AML1/ETO, showing that the competition by the chimeric protein was specific for PEBP2
B1 and RAD (Fig. 5D). The
significance of this observation will be discussed below.
One of the reasons why physiological roles of the nuclear matrix have
not been established is that the nuclear matrix fraction is prepared
under harsh conditions, and therefore, it may not represent
biologically active material (10). On the other hand, the
"nuclear skeleton" fraction is prepared under physiological conditions (27). We therefore examined whether PEBP2
B1
can be recovered in the nuclear skeleton fraction. As shown in Fig. 5E,
full-length PEBP2
B1 was retained in the nuclear skeleton fraction
(lane 1). The C-terminal truncation up to aa 371 did not affect the
property (lane 2). However, the C-terminal deletion up to aa 291 completely abolished the ability of PEBP2
B1 to associate with the
nuclear skeleton (lane 3). The result was entirely compatible with
those obtained by using the nuclear matrix fraction (31) and
suggests that PEBP2
B1 is tightly attached to the nuclear insoluble
material under physiological conditions.
AML1/ETO inhibited PEBP2
B1-dependent Py DNA
replication.
Since AML1/ETO was able to compete with
PEBP2
B1 for nuclear matrix attachment, we tested whether the
chimeric protein could inhibit PEBP2
B1 DNA replication activity
(Fig. 6). In this study, we compared the
properties of AML1/ETO, CH15, and 1-185, all of which have been shown
to be nuclear proteins (reference 31 and data not
shown).
|
subunit, because the
subunit dimerizes with the Runt domain and enhances the DNA binding
activity of the
subunit. The results are shown in Fig. 6A. 1-185 by
itself was able to bind strongly to DNA. The
subunit supershifted
the band and increased its intensity. Despite the fact that AML1/ETO
contains the intact Runt domain, it hardly interacted with DNA, even in
the presence of the
subunit (Fig. 6A). CH15, on the other hand,
bound poorly to DNA, but its binding was enhanced by the
subunit
(Fig. 6A). None of these proteins were able to stimulate Py DNA
replication by themselves (Fig. 6B), which is consistent with the
notion that they lack RAD. Cotransfection of increasing amounts of
plasmids expressing AML1/ETO progressively inhibited
PEBP2
B1-dependent Py DNA replication (Fig. 6C, lanes 1 to 5).
However, inhibition by CH15 and 1-185 was far less effective than by
AML1/ETO (Fig. 6C, lanes 6 to 9 and 10 to 13, respectively). When the
ratio of the plasmids expressing chimeric or truncated proteins to
PEBP2
B1 was 4 to 1, AML1/ETO, CH15 and 1-185 reduced replication
activity to 18, 92, and 74%, respectively (Fig. 6C, compare lanes 4, 8, and 12). From these results we concluded that a mechanism other than
competition for a common DNA binding site was involved in the
inhibition by the chimeric protein. The results also indicated that the
C-terminal 357-aa region of ETO was required for the inhibitory effect.
Consistent with this conclusion, AML1/ETO effectively inhibited the
replication of pPyG5OICAT stimulated by GAL4-RAD, whereas neither CH15
nor 1-185 had any effect on replication (Fig. 6D). Since pPyG5OICAT
does not have the PEBP2 binding site, the results clearly showed that
AML1/ETO inhibited RAD-dependent replication without binding to the
reporter plasmid. However, the possibility remained that the effect of
the chimeric protein was indirect and nonspecific. For example,
expression of AML1/ETO might inhibit the expression of TAg or might be
toxic for the cells. To test this possibility, we examined the
influence of the chimeric protein on replication activated by
GAL4-VP16. AML1/ETO hardly inhibited the replication of the reporter
plasmid (Fig. 6E), indicating that AML1/ETO specifically inhibited
RAD-dependent replication. Moreover, the fact that AML1/ETO did not
inhibit basal replication observed in the absence of effectors
confirmed this conclusion (Fig. 6B, lanes 3 to 6). The results shown in
Fig. 5 and 6 suggest that nuclear matrix localization is necessary for
the stimulation of Py DNA replication by PEBP2
B1 and that inhibition
of replication activity by AML1/ETO is, at least partly, due to the
elimination of PEBP2
B1 from the nuclear matrix compartment by the
chimeric protein.
Mutational analysis of RAD.
In order to determine which amino
acids in the activation domain are important for replication
activation, we introduced a series of mutations into RAD. We chose
highly conserved amino acids common to PEBP2
B1, PEBP2
A1, and
PEBP2
C1 as targets for mutation, since PEBP2
A1 and PEBP2
C1
also strongly stimulate Py DNA replication (data not shown). Figure
7A shows a sequence comparison of RAD
with the corresponding regions of PEBP2
A1 and PEBP2
C1 and the
sites of each of the mutations. We made six mutants, termed M1 through
M6. Each mutant had three amino acid substitutions. The mutated 70-aa
fragments were fused to the GAL4 DNA binding domain and were tested for
replication stimulation activity. As shown in Fig. 7B, M1, M2, M3, and
M6 showed almost the same activity as the wild type, whereas two
mutants, M4 and M5, displayed only 10 to 20% of the activity of the
wild type. Since all six proteins bound to the GAL4 binding site as
efficiently as the wild-type fusion protein as revealed by EMSA (data
not shown) and both M4 and M5 still localized in the nuclear matrix
(Fig. 7C), the decrease in the activities of M4 and M5 would appear to
be due to the loss of affinity for some replication related protein(s)
required for Py DNA replication (see below).
|
RAD competed with the full-length PEBP2
B1 for activation of Py
DNA replication.
Based on our earlier observations (26)
and the results of mutational analysis shown above, we assumed that RAD
interacts with proteins involved in DNA replication. If this assumption is correct, overexpression of the non-DNA binding activation domain should compete with PEBP2
B1 for the putative target replication protein(s), resulting in the inhibition of the PEBP2
B1-dependent Py
DNA replication. We cotransfected a constant amount of full-length PEBP2
B1 expression plasmids and Py(AE)4OICAT, together
with increasing amounts of plasmids expressing GAL4-RAD, into the cells
(Fig. 8A). The stimulation activity of
PEBP2
B1 was observed to gradually decrease with the increase in the
amount of GAL4-RAD (Fig. 8A, lanes 1 to 6). This was in contrast to the
absence of any effect when the M4 (Fig. 8A, lanes 8 to 13) and M5
mutant (data not shown) proteins were used to replace GAL4-RAD under
the same conditions. Since the reporter plasmid,
pPy(AE)4OICAT, did not contain the GAL4 binding site, the
overexpressed GAL4 fusion protein did not stimulate the replication
activity of the reporter plasmid by itself (Fig. 8A, lanes 7 and 14).
The results suggest that PEBP2
B1 interacts with replication
protein(s) for its activity to stimulate replication, if the nuclear
matrix localization of PEBP2
B1 is not affected by cotransfected
GAL4-RAD or M4. In fact, overexpression of GAL4-RAD, M4, or M5 mutant
protein did not compete with PEBP2
B1 for the nuclear matrix
localization (Fig. 8B and data not shown for M5). The reason for the
lack of competition for the nuclear matrix localization is clarified
below.
|
B1
which has the nuclear matrix localization activity. There is the second
nuclear matrix localization activity between aa 371 and 451 (31). This explains why overexpression of GAL4-RAD or its
mutant did not inhibit the nuclear matrix localization of the
full-length PEBP2
B1 as shown in Fig. 8B: RAD may not have competed
with the second nuclear matrix localization signal. In order to test
whether this explanation is genuine, we examined whether overexpression
of GAL4-RAD or its mutant would inhibit the nuclear matrix localization
of the truncated PEBP2
B1 lacking the second nuclear matrix
localization signal (Fig. 8C). As expected, GAL4-RAD (Fig. 8C, lanes 2 to 4), M4 (lanes 5 to 7), and M5 (data not shown) all inhibited the
nuclear matrix localization of PEBP2
B1(1-371) in a dose-dependent
manner. The extent of inhibition was 54% (Fig. 8C, lane 4) and 49%
(lane 7) at the highest amount of the competitor (16 µg) for GAL4-RAD
and M4, respectively, suggesting that the M4 mutation does not affect
the nuclear matrix targeting of RAD. Then, we examined the replication
stimulation activity of PEBP2
B1(1-371) (Fig. 8D). We observed that
the replication activity was about 18% at the highest amount of the
competitor (16 µg) in the presence of GAL4-RAD (Fig. 8D, lane 4),
whereas it was about 53% in the presence of M4 (lane 7).
The results shown in Fig. 8D appear to reflect two types of
competition. The first is the competition at the level of nuclear matrix binding: the reduction of replication activity observed with M4
to 53% (Fig. 8D, lane 7) was well correlated with the reduction of the
amount of M4 in the nuclear matrix fraction to 49% under the same
conditions (Fig. 8C, lane 7). The amount of GAL4-RAD was also reduced
to about half under the same conditions (Fig. 8C, lane 4), yet the
replication activity was down to 18% (Fig. 8D, lane 4). The additional
reduction of the replication activity of GAL4-RAD must be due to the
competition of the replication protein(s) interacting with RAD. This
set of the results shown in Fig. 8C and D once again reinforced the
conclusion described above that the initiation of replication depends
on the presence of RAD in the nuclear matrix.
The results shown in Fig. 8 altogether strongly suggested that the
PEBP2
B1 must interact with one or more proteins necessary for Py DNA
replication through the region of RAD affected by the M4 and M5
mutations.
GAL4-VP16 stimulated Py DNA replication as efficiently as GAL4-RAD
(Fig. 4A). VP16 was shown to interact with RP-A, and the interaction is
thought to be important for the stimulation of Py DNA replication
(35). Overexpression of GAL4-VP16, however, did not affect
the replication stimulated by PEBP2
B1 (Fig. 8E, lanes 2 to 4),
whereas GAL4-RAD severely inhibited this activity (lanes 5 to 7). This
result suggested that the target protein of PEBP2
B1 is different
from RP-A or other VP16 binding proteins.
In addition to RP-A, TAg is a possible target of transcription factors
that stimulate Py DNA replication (26). We tested whether
RAD and TAg interact directly by using surface plasmon resonance
measurements in a BIAcore instrument. However, no direct interaction
between RAD and TAg could be detected under conditions that allow
detection of the interaction between c-Jun and TAg. In addition, under
conditions that allowed detection of the interaction between VP16 and
RP-A, we were unable to observe any interaction of RAD with RP-A (data
not shown).
DISCUSSION
|
|
|---|
A growing body of evidence suggests the importance of the nuclear
matrix in DNA replication. However, there exists relatively little
evidence to show that the nuclear matrix domains are important for the
control of DNA replication. This report shows that the replication
activity of a transcription factor, PEBP2
B1, depends on its location
in the nuclear matrix. PEBP2
B1 stimulated the initiation of Py DNA
replication, and the minimal RAD was found to correspond to a region of
70 aa between aa 302 and 371. In addition the RAD was found to harbor a
region responsible for the association of PEBP2
B1 with the nuclear
matrix, which was inhibited by the chimeric protein AML1/ETO.
Furthermore, the nuclear matrix association of RAD appears to be
essential for the ability of GAL4-RAD to stimulate Py DNA replication.
Thus, this report is the first indication of a strong correlation
between the initiation of DNA replication and the targeting of a
protein with replication stimulation activity to the nuclear matrix
compartment. This simple system should be useful to further investigate
the role of the nuclear matrix in DNA replication.
It is not known at present whether Py DNA replication takes place in a subnuclear structure such as the replication foci observed in cellular DNA replication. However, it is conceivable that Py DNA replication also takes place in such a structure on the nuclear matrix, since the DNA replication of herpes simplex virus and adenovirus takes place in the subnuclear structure (33, 53). If so, targeting of the replication origin to the replication factory would be an important step for the initiation of Py DNA replication. Therefore, we suggest that the nuclear matrix localization activity of RAD enhances Py DNA replication by recruiting the origin to the replication factory on the nuclear matrix. Alternatively, it is possible that the targeting to the nuclear matrix is required for RAD to interact properly with a protein present in the replication factory. The finding that VP16 is also localized in the nuclear matrix may suggest that targeting to the nuclear matrix is a common feature of transcription factors that stimulate Py DNA replication.
At this stage, it is not clear how PEBP2
B1 and GAL4-RAD are targeted
to the nuclear matrix. Direct or indirect interaction between the
signal sequence and the nuclear matrix protein(s) may be involved in
the localization. It is interesting that both VP16 and RAD interact
with the nuclear matrix, yet only the association of the latter is
inhibited by AML1/ETO. We assume that more than one nuclear
matrix-targeting signal exists and that each of them interacts with a
different set of targets. Further analysis of the nuclear matrix
targeting signals will be required to clarify the mechanism. Of
particular importance will be the necessity to identify the protein(s)
that associates with the nuclear matrix-targeting sequence.
Our data clearly indicate that nuclear matrix targeting alone is not
enough for the stimulation of Py DNA replication, since mutant RADs (M4
and M5) that had lost DNA replication activity were still localized in
the nuclear matrix. From the competition experiments, we concluded that
the activation domain of PEBP2
B1 interacts with protein(s) involved
in the initiation of Py DNA replication and that M4 and M5 mutations
disturb these interactions. What is the target protein of RAD for the
stimulation of replication?
Initiation of Py DNA replication consists of multiple steps. First,
chromatin structure around the origin must be opened for the binding of
TAg. TAg forms a double hexamer in an ATP-dependent manner which
induces a structural change in the DNA at the ori-core . Then, unwinding of double-stranded DNA starts in the presence of RP-A.
Finally, DNA polymerase
-primase starts DNA synthesis on the unwound
DNA covered with RP-A. Some of the transcription factors that stimulate
Py DNA replication were shown to interact with the proteins involved in
the initiation steps. VP16, p53, E2, and GAL4 interact with RP-A
(13, 21, 35). Recently, we showed that c-Jun interacts with
TAg and stimulates the formation of the TAg-origin complex
(26). In this study, we were unable to detect any
interaction of RAD with RP-A or TAg, suggesting that RAD interacts with
proteins involved in another step(s) such as the one before the
formation of the TAg-origin complex or after unwinding. One of the
candidates could be DNA polymerase
-primase. However, we were unable
to detect a direct interaction between RAD and DNA polymerase
-primase in the assay using the BIAcore (data not shown).
A factor involved in chromatin remodeling could be a target protein. Experiments using the in vitro simian virus 40 system indicated that the assembly of the origin DNA into chromatin structure inhibits the binding of simian virus 40 TAg to the origin, with a consequent negative effect on the initiation of replication (8, 25). Moreover, Cheng and Kelly showed that prebinding of the transcription factor (NFI and GAL4-VP16) relieved the inhibitory effect of chromatin in an activation domain-dependent manner (8, 9). In the case of the initiation of transcription, chromatin formation is also inhibitory, and thus, remodeling of chromatin is important for gene activation. For example, chromatin-remodeling factors, such as SWI/SNF and NURF, have been identified as transcriptional regulators (48). More recently, the coactivator-adapter complexes for transcription were shown to contain histone acetyltransferase activity which can alter chromatin structure by acetylating histone tails (49). Therefore, it is attractive to speculate that RAD interacts with proteins that alter chromatin structure to assist the binding of TAg or other replication proteins to the origin.
We showed that the GAL4-RAD fusion protein did not stimulate
transcription in P19 cells from the Py early promoter containing the
GAL4 site. However, it should be noted that the transcription activation domain (TAD) of PEBP2
B1 was mapped to a region between aa
291 and 371 by using a GAL4 fusion protein in Jurkat or U937 cells and
a reporter plasmid containing a GAL4 binding site linked to the
herpesvirus thymidine kinase gene (31). In other words, TAD
(aa 291 to 371) largely overlaps RAD (aa 302 to 371). In addition, using the same reporter, we detected weak but reproducible
transcription activity of the same GAL4 fusion protein containing aa
291 to 371 in P19 cells while GAL4-RAD containing aa 302 to 371 barely showed the activity (data not shown). We speculate that TAD interacts with transcription-related protein(s) to exert its function while RAD
interacts with replication-related proteins. However, the fact that TAD
and RAD regions are coincident suggests that the activities have a
common molecular basis. This might simply be nuclear matrix targeting.
If so, this 80-aa region may represent a major nuclear matrix targeting
signal. However, we found that a region closer to the C terminus is
equally effective in nuclear matrix targeting. Alternatively,
interaction with a chromatin remodeling factor(s) might provide a
common mechanism. In any case, further analysis is required to clarify
the nature of the underlying mechanism.
We used Py DNA replication as a model system for cellular DNA replication. The critical question is whether transcription factors actually participate in the initiation of cellular DNA replication. Participation of transcription factors in cellular DNA replication was first indicated for S. cerevisiae ARS1 function. In ARS1, the activation domains of transcription factors such as ABF1, RAP1, and GAL4 were found to stimulate replication (36). Interestingly, RAP1 was shown to be localized in the nuclear scaffold (32). In addition, autonomously replicating sequences are associated with the nuclear matrix in yeast. Therefore, it is conceivable that cellular DNA replication in yeast takes place in the nuclear matrix and that transcription factors play an important role in initiation. In mammalian cells, many putative replication origins have been identified. In almost all cases, the origin maps to a promoter-enhancer region or includes multiple transcription factor binding sites (11). It was also shown at the beginning of S phase that a significant number of replication foci and transcription foci coincide (19). This result is consistent with the long-standing observation that transcriptionally active genes tend to replicate early in S phase (20). In general, these results are in good agreement with the involvement of transcription factors in the regulation of DNA replication in mammalian cells.
It is still not clear how the leukemogenic chimeric protein AML1/ETO
induces leukemia. From this point of view, it will be worth examining
whether the ability of AML1/ETO to interfere with RAD is related to its
leukemogenic potential. It is possible that through the inhibition of
nuclear matrix localization, the chimeric protein disturbs the control
of DNA replication and transcription mediated by PEBP2
B1, eventually
resulting in the leukemogenic state of the cell. A more detailed
analysis of the relationship between nuclear matrix association and
stimulation of replication and transcription, in addition to the
identification of the target protein of RAD, should provide us with
important clues about the mechanism of leukemogenesis induced by these
chimeric proteins.
ACKNOWLEDGMENTS
|
|
|---|
We thank T. Era (Kumamoto University) for generously providing the plasmids for the expression of the AML1/ETO and CH15.
This study was supported in part by a grant-in-aid for Priority Area on Cancer Research from the Minister of Education, Science and Culture, Japan, to Y.I. (contract no. 09253220).
FOOTNOTES
* Corresponding author. Mailing address: Department of Viral Oncology, Institute for Virus Research, Kyoto University, Shogoin, Sakyo-ku, Kyoto 606, Japan. Phone: 81-75-751-4028. Fax: 81-75-752-3232. E-mail: yito{at}virus.kyoto-u.ac.jp.
REFERENCES
|
|
|---|
| 1. | Amati, B. B., and S. M. Gasser. 1988. Chromosomal ARS and CEN elements bind specifically to the yeast nuclear scaffold. Cell 54:967-978[Medline]. |
| 2. |
Amati, B. B., and S. M. Gasser.
1990.
Drosophila scaffold-attached regions bind nuclear scaffolds and can function as ARS elements in both budding and fission yeasts.
Mol. Cell. Biol.
10:5442-5454 |
| 3. |
Bae, S. C.,
E. Ogawa,
M. Maruyama,
H. Oka,
M. Sataka,
K. Shigesada,
N. A. Jenkins,
D. J. Gilbert,
N. G. Copeland, and Y. Ito.
1994.
PEBP2 B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials.
Mol. Cell. Biol.
14:3242-3252 |
| 4. |
Bae, S. C.,
E. Takahashi,
Y. W. Zhang,
E. Ogawa,
K. Shigesada,
Y. Namba,
M. Sataka, and Y. Ito.
1995.
Cloning, mapping and expression of PEBP2 C, a third gene encoding the mammalian Runt domain.
Gene
159:245-248[Medline].
|
| 5. | Baru, M., M. Shlissel, and H. Manor. 1991. The yeast GAL4 protein transactivates the polyomavirus origin of DNA replication in mouse cells. J. Virol. 65:3494-3503. |
| 6. | Bennett-Cook, E. R., and J. A. Hassell. 1991. Activation of polyomavirus DNA replication by yeast GAL4 is dependent on its transcriptional activation domains. EMBO J. 10:959-969[Medline]. |
| 7. |
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752 |
| 8. | Cheng, L. Z., and T. J. Kelly. 1989. Transcriptional activator nuclear factor 1 stimulates the replication of SV40 minichromosomes in vivo and in vitro. Cell 59:541-551[Medline]. |
| 9. |
Cheng, L. Z.,
J. L. Workman,
R. E. Kingston, and T. J. Kelly.
1992.
Regulation of DNA replication in vitro by the transcription activation domain of GAL4-VP16.
Proc. Natl. Acad. Sci. USA
89:589-593 |
| 10. |
Cook, P. R.
1988.
The nuclear skeleton: artefact, passive framework or active site?
J. Cell Sci.
90:1-6 |
| 11. | DePamphilis, M. L. 1993. Eukaryotic DNA replication: anatomy of an origin. Annu. Rev. Biochem. 62:29-63[Medline]. |
| 12. | de Villiers, J., W. Schaffner, C. Tyndall, S. Lupton, and R. Kamen. 1984. Polyoma virus DNA replication requires an enhancer. Nature 312:242-246[Medline]. |
| 13. | Dutta, A., J. M. Ruppert, J. C. Aster, and E. Winchester. 1993. Inhibition of DNA replication factor RPA by p53. Nature 365:79-82[Medline]. |
| 14. | Era, T., N. Asou, T. Kunisada, H. Yamasaki, H. Asou, N. Kamada, S. Nishikawa, K. Yamaguchi, and K. Takatsuki. 1995. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells. Genes Chromosomes Cancer 13:25-33[Medline]. |
| 15. |
Erickson, P.,
J. Gao,
K.-S. Chang,
T. Look,
E. Whisenant,
S. Raimondi,
R. Lasher,
J. Trujillo,
J. Rowley, and H. Drabkin.
1992.
Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.
Blood
80:1825-1831 |
| 16. | Fujii, M., H. Tsuchiya, and M. Seiki. 1991. HTLV-1 Tax has distinct but overlapping domains for transcriptional activation and enhancer specificity. Oncogene 6:2349-2352[Medline]. |
| 17. |
Golling, G.,
L.-H. Li,
M. Pepling,
M. Stabbins, and J. P. Gergen.
1996.
Drosophila homologs of the proto-oncogene product PEBP/CBF regulate the DNA-binding properties of Runt.
Mol. Cell. Biol.
16:932-942[Abstract].
|
| 18. |
Guo, Z.-S., and M. L. DePamphilis.
1992.
Specific transcription factors stimulate simian virus 40 and polyomavirus origins of DNA replication.
Mol. Cell. Biol.
12:2514-2524 |
| 19. | Hassan, A. B., R. J. Errington, N. S. White, D. A. Jackson, and P. R. Cook. 1994. Replication and transcription sites are colocalized in human cells. J. Cell Sci. 107:425-434[Abstract]. |
| 20. |
Hatton, K. S.,
V. Dhar,
E. H. Brown,
M. A. Iqbal,
S. Stuart,
V. T. Didamo, and C. L. Schildkraut.
1988.
Replication program of active and inactive multigene families in mammalian cells.
Mol. Cell. Biol.
8:2149-2158 |
| 21. | He, Z., B. T. Brinton, J. Greenblatt, J. A. Hassell, and C. J. Ingles. 1993. The transactivation proteins VP16 and GAL4 bind replication factor A. Cell 73:1223-1232[Medline]. |
| 22. | Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:265-269. |
| 23. | Hozak, P., A. B. Hassan, D. A. Jackson, and P. R. Cook. 1993. Visualization of replication factories attached to a nucleoskeleton. Cell 73:361-373[Medline]. |
| 24. | Ishikawa, H., M. Asano, T. Kanda, S. Kumar, C. Gelinas, and Y. Ito. 1993. Two novel functions associated with the Rel oncoproteins: DNA replication and cell-specific transcriptional activation. Oncogene 8:2889-2896[Medline]. |
| 25. |
Ishimi, Y.
1992.
Preincubation of LT antigen with DNA overcomes repression of SV40 DNA replication by nucleosome assembly.
J. Biol. Chem.
267:10910-10913 |
| 26. | Ito, K., M. Asano, P. Hugues, H. Kohzaki, C. Masutani, F. Hanaoka, T. Kerppola, T. Curran, Y. Murakami, and Y. Ito. 1996. c-Jun stimulates origin-dependent DNA unwinding by polyomavirus large T antigen. EMBO J. 15:5636-5646[Medline]. |
| 27. |
Jackson, D. A.,
J. Yuan, and P. R. Cook.
1988.
A gentle method for preparing of cyto- and nucleo-skeletons and associated chromatin.
J. Cell Sci.
90:365-378 |
| 28. | Kagoshima, H., M. Satake, H. Miyoshi, M. Ohki, |